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Abstract
Men who have sex with men (MSM) especially those who are HIV positive are at risk for HPV-associated anal cancer.
We systematically reviewed studies with data on the prevalence of vaccine preventable anal HPV among men who
have sex with men aged 25 or younger and identified 6 studies. None of these studies were specifically designed
to determine the prevalence of HPV in this population. Available data, albeit limited, suggest many young MSM
may not already be HPV infected. Further studies using representative sampling focused on teenage MSM are
required to confirm this.
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Background
Genital human papillomavirus (HPV) infection is wide-
spread [1-3] and usually asymptomatic [4]. HPV types 6
and 11 are the types most commonly associated with
anogenital warts [5], while types 16 and 18 are asso-
ciated with HPV related malignancies including anal and
cervical cancer [1-3,6]. Studies demonstrate that the
great majority of adult MSM are infected with multiple
HPV types [7-9], with a substantial proportion infected
with HPV 16 or 18, which together cause about 80% of
anal cancers [10-12]. MSM especially those who are HIV
positive are at increased risk for anal cancer [13].
The prophylactic quadrivalent HPV vaccine is effective
in preventing infection with HPV types 6, 11, 16 and 18
and in reducing the incidence of anogenital warts and
anal intraepithelial neoplasia in males [14,15]. However,
to date no countries have introduced universal, free vac-
cination of boys. The extent to which young MSM are
already infected with HPV at the age at which targeted
vaccination is available is not well documented. We
therefore undertook a review of studies examining the
prevalence of HPV among MSM aged 25 and younger.
Methods
We systematically reviewed studies by searching MEDLINE
and abstracts from the European Research Organisation on
Genital Infection and Neoplasia (EUROGIN) Conferences
and the International Papillomavirus (IPV) Conferences.
Key words used in the search included: “men who have
sex with men” or “MSM” or “homosexual” or “bisexual” or
“gay” and “human papillomavirus” or “HPV”.
The following data were extracted: author, year of pub-
lication, study setting, number of MSM, number of
MSM aged 25 or younger, sample collection method,
HPV DNA testing method, and HPV type tested. HPV
6/11/16/18 prevalence were extracted, and where pos-
sible, HPV 6/11/16/18 prevalence stratified by age group
(≤20 years old; 21–25 years old; ≤25 years old).
Results
The outcome of the review is summarized in Figure 1.
The study populations, selection criteria, testing meth-
ods for HPV and HPV types covered in the 6 studies
included are presented in Table 1. Importantly, none of
the studies specifically sought to determine the preva-
lence of HPV infection among a representative sample
of young MSM [7,16-19].
The 6 studies included provided data on anal HPV for
a total of 698 MSM aged ≤ 25. Among men aged ≤ 20,
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Figure 1 Selection procedure for studies of anal HPV prevalence among HIV-negative MSM25 years. AIN:anal intraepithelial neoplasia;
PCR: polymerase chain reaction; hybrid capture.
Table 1 Overview of studies with data on anal HPV detection among men who have sex with men aged ≤ 25 years
Author,
year
















(i) Homosexual men attending
an STD clinic in Seattle (ii)
Homosexual men attending a
community-based clinic for HIV
screening in Seattle
(i) Age 16–50; being
homosexual or bisexual. (ii)







33, 35,39 and 45
Moscicki,
2003 [18]
Adolescents in primary care
centres in 13 US cities who were
at high risk of HIV infection












MSM from the general
population, universities, STD
clinics and organized health care
systems in Sao Paulo,
Cuernavaca, Tampa.
Age 18–70; having no prior
penile or anal cancer or



















Age ≥19; identifying as a











MSM in a randomized, placebo-
controlled, double-blinded trial of
HPV vaccination in 14 countries
Age 16–26; having ≤ 5
lifetime male and/or female















a Number of HIV negative MSM ≤ 25 years old for whom data on anal HPV DNA was provided by the authors.
b Combined data from two separate studies (i and ii) provided by the author.
c 58 men who were HIV positive were excluded.
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the prevalence of anal HPV 6, 11, 16 and 18 ranged from
0 to 17%, 0 to 17%, 0 to 14% and 0 to 20%, respectively.
Among men aged 21 to 25, the prevalence of anal HPV
6, 11, 16 and 18 ranged from 8 to 19%, 0 to 8%, 0 to
18% and 3 to 8%, respectively.
Discussion
Through this review, we found that there have been no
published studies that have been designed to specifically
determine the prevalence of HPV among young MSM
using a representative sample of young MSM. Of the six
studies identified, all had potential biases because of the
way the studies were designed. These could have led to ei-
ther an overestimate or an underestimate of the true HPV
prevalence among young MSM. Several studies recruited
men from clinics including STD clinics [7,17,18] while
others had selection criteria that may have led to higher
risk or lower risk men being included [15,19]. Several
studies recruited MSM across a wider age range leaving
only a much smaller subset of younger MSM with data on
HPV prevalence. Most data derive from a study that was
designed to determine HPV vaccine efficacy in MSM ra-
ther than HPV prevalence [15]. A further limitation is that
all studies only reported HPV detection at a single time
point rather than defining infection by the presence of the
same HPV type present at two separate time points.
Despite these important limitations, the available data
suggest HPV infection may still be uncommon among
teenage same sex attracted males, although the data are
currently insufficient to draw this conclusion with confi-
dence. A community-based, representative sample is
needed to determine the prevalence of HPV infection,
defined rigorously, among mainly teenage same sex
attracted males.
Given that HPV 16 and 18 are responsible for around
80% of anal cancers [12] and HPV 6 and 11 account for
most genital warts [21] such a study would help to as-
certain whether targeted HPV vaccination of young
MSM is likely to be effective in preventing anal cancer
in this group of at-risk males. Ideally, HPV vaccination
should occur prior to the onset of sexual activity –
ahead of potential HPV acquisition. To date, however,
no country has implemented universal HPV vaccination
of school aged boys, although the Australian Govern-
ment has recently announced it is planning to roll out
the HPV vaccination program to 12 and 13 years old
schoolboys from 2013. Targeted vaccination of MSM to
prevent anal cancer would likely only be effective if, in
addition to low existing HPV rates, young same sex
attracted males are willing to disclose their sexuality to
health care providers in order to obtain the HPV vac-
cine. Further studies to determine the acceptability and
feasibility of targeted vaccination of young same sex
attracted males are required.
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